Literature DB >> 7058341

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

P J Whitehouse, D L Price, R G Struble, A W Clark, J T Coyle, M R Delon.   

Abstract

Recent evidence indicates that the nucleus basalis of Meynert, a distinct population of basal forebrain neurons, is a major source of cholinergic innervation of the cerebral cortex. Postmortem studies have previously demonstrated profound reduction in the presynaptic markers for cholinergic neurons in the cortex of patients with Alzheimer's disease and senile dementia of the Alzheimer's type. The results of this study show that neurons of the nucleus basalis of Meynert undergo a profound (greater than 75 percent) and selective degeneration in these patients and provide a pathological substrate of the cholinergic deficiency in their brains. Demonstration of selective degeneration of such neurons represents the first documentation of a loss of a transmitter-specific neuronal population in a major disorder of higher cortical function and, as such, points to a critical subcortical lesion in Alzheimer's patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7058341     DOI: 10.1126/science.7058341

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  567 in total

1.  beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons.

Authors:  Q Liu ; H Kawai; D K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  DNA replication precedes neuronal cell death in Alzheimer's disease.

Authors:  Y Yang; D S Geldmacher; K Herrup
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

3.  Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease.

Authors:  S I Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Muscarinic tone sustains impulse flow in the septohippocampal GABA but not cholinergic pathway: implications for learning and memory.

Authors:  M Alreja; M Wu; W Liu; J B Atkins; C Leranth; M Shanabrough
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

5.  Past glory and future promise: maximizing and improving understanding of atrophy patterns in the diagnosis of degenerative dementias.

Authors:  Bruce L Miller
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 6.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

7.  Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.

Authors:  T T Soncrant; K C Raffaele; S Asthana; A Berardi; P P Morris; J V Haxby
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

9.  Nucleus raphe dorsalis in parkinsonism-dementia complex of Guam.

Authors:  T Yamamoto; A Hirano
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

10.  Monoclonal antibody cross-reactions between Drosophila and human brain.

Authors:  C A Miller; S Benzer
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.